Thyroid Gland Anaplastic Carcinoma

News alerts, weekly reports and conference planners

Related cancers:

‹

Thyroid Gland Carcinoma (359)

Thyroid Gland Medullary Carcinoma (61)

Thyroid Gland Papillary Carcinoma (58)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Hurthle Cell Carcinoma (12)

Thyroid Gland Carcinoma (359)

Thyroid Gland Medullary Carcinoma (61)

Thyroid Gland Papillary Carcinoma (58)

Thyroid Gland Follicular Carcinoma (25)

Thyroid Gland Hurthle Cell Carcinoma (12)

›

BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1	trametinib + dabrafenib Sensitive: A1 - Approval trametinib + dabrafenib Sensitive : A1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1	dabrafenib Sensitive: A1 - Approval dabrafenib Sensitive : A1
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	Sensitive: A2 - Guideline Sensitive : A2	Sensitive: A2 - Guideline Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	docetaxel + doxorubicin hydrochloride Sensitive: A2 - Guideline docetaxel + doxorubicin hydrochloride Sensitive : A2	docetaxel + doxorubicin hydrochloride Sensitive: A2 - Guideline docetaxel + doxorubicin hydrochloride Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2	doxorubicin hydrochloride Sensitive: A2 - Guideline doxorubicin hydrochloride Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2	paclitaxel Sensitive: A2 - Guideline paclitaxel Sensitive : A2
NTRK3 fusion	Thyroid Gland Anaplastic Carcinoma	NTRK3 fusion	Thyroid Gland Anaplastic Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma	NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Anaplastic Carcinoma	NTRK1 fusion	Thyroid Gland Anaplastic Carcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Thyroid Gland Anaplastic Carcinoma	NTRK1 fusion	Thyroid Gland Anaplastic Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma	NTRK2 fusion	Thyroid Gland Anaplastic Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK3 fusion	Thyroid Gland Anaplastic Carcinoma	NTRK3 fusion	Thyroid Gland Anaplastic Carcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
RET mutation	Thyroid Gland Anaplastic Carcinoma	RET mutation	Thyroid Gland Anaplastic Carcinoma	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2	selpercatinib Sensitive: A2 - Guideline selpercatinib Sensitive : A2
TMB-H	Thyroid Gland Anaplastic Carcinoma	TMB-H	Thyroid Gland Anaplastic Carcinoma	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2	carboplatin + paclitaxel Sensitive: A2 - Guideline carboplatin + paclitaxel Sensitive : A2
RET fusion	Thyroid Gland Anaplastic Carcinoma	RET fusion	Thyroid Gland Anaplastic Carcinoma	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2	pralsetinib Sensitive: A2 - Guideline pralsetinib Sensitive : A2
No biomarker	Thyroid Gland Anaplastic Carcinoma	No biomarker	Thyroid Gland Anaplastic Carcinoma	AIC100 Sensitive: B - Late Trials AIC100 Sensitive : B	AIC100 Sensitive: B - Late Trials AIC100 Sensitive : B
EGFR L858R	Thyroid Gland Anaplastic Carcinoma	EGFR L858R	Thyroid Gland Anaplastic Carcinoma	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1	erlotinib Sensitive: C1 - Off-label erlotinib Sensitive : C1
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	vemurafenib Resistant: C1 - Off-label vemurafenib Resistant : C1	vemurafenib Resistant: C1 - Off-label vemurafenib Resistant : C1
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + cobimetinib Sensitive : C2	atezolizumab + cobimetinib Sensitive: C2 – Inclusion Criteria atezolizumab + cobimetinib Sensitive : C2
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2	vemurafenib Sensitive: C2 – Inclusion Criteria vemurafenib Sensitive : C2
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3	FORE-8394 + cobicistat Sensitive: C3 – Early Trials FORE-8394 + cobicistat Sensitive : C3
PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma	PD-L1 overexpression	Thyroid Gland Anaplastic Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
TMB-H	Thyroid Gland Anaplastic Carcinoma	TMB-H	Thyroid Gland Anaplastic Carcinoma	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3	pembrolizumab + lenvatinib Sensitive: C3 – Early Trials pembrolizumab + lenvatinib Sensitive : C3
BRAF mutation	Thyroid Gland Anaplastic Carcinoma	BRAF mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + vemurafenib Sensitive: C3 – Early Trials atezolizumab + vemurafenib Sensitive : C3	atezolizumab + vemurafenib Sensitive: C3 – Early Trials atezolizumab + vemurafenib Sensitive : C3
NF1 mutation	Thyroid Gland Anaplastic Carcinoma	NF1 mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
KRAS mutation	Thyroid Gland Anaplastic Carcinoma	KRAS mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
RAS mutation	Thyroid Gland Anaplastic Carcinoma	RAS mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
NF2 mutation	Thyroid Gland Anaplastic Carcinoma	NF2 mutation	Thyroid Gland Anaplastic Carcinoma	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3	atezolizumab + cobimetinib Sensitive: C3 – Early Trials atezolizumab + cobimetinib Sensitive : C3
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF inhibitor Sensitive: C3 – Early Trials BRAF inhibitor Sensitive : C3	BRAF inhibitor Sensitive: C3 – Early Trials BRAF inhibitor Sensitive : C3
NTRK3 positive	Thyroid Gland Anaplastic Carcinoma	NTRK3 positive	Thyroid Gland Anaplastic Carcinoma	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3	larotrectinib Sensitive: C3 – Early Trials larotrectinib Sensitive : C3

Thyroid Gland Anaplastic Carcinoma

Associations(70)

Associations
(70)